| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184604 | Gynecologic Oncology | 2012 | 5 Pages |
Abstract
⺠The maximum tolerated dose and feasibility of IV docetaxel, IP carboplatin and IP paclitaxel were assessed. ⺠First cycle RPII Dose did not predict toxicity over multiple cycles.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Natalie Gould, Michael W. Sill, Robert S. Mannel, Premal H. Thaker, Paul A. DiSilvestro, Steven E. Waggoner, S. Diane Yamada, Deborah K. Armstrong, Paula M. Fracasso, Joan L. Walker,